Menu Search
Equities

Sihuan Pharmaceutical Holdings Group Ltd

TEL1:STU

Sihuan Pharmaceutical Holdings Group Ltd

Actions
  • Price (EUR)0.054
  • Today's Change-0.001 / -0.92%
  • Shares traded0.00
  • 1 Year change-28.48%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)2.01bn
  • Net income in HKD-58.32m
  • Incorporated2006
  • Employees2.87k
  • Location
    Sihuan Pharmaceutical Holdings Group Ltd21/F, Building 2,Zhbng 2000 Bsns CtrWest BalizhuangChaoyang DistrictBEIJING 100025ChinaCHN
  • Phone+86 75 588609726
  • Fax+86 1 052278758
  • Websitehttp://www.sihuanpharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.